When measuring associations with metastatic disease at presentation, TNF antagonist use trended towards an association with reduced metastases at diagnosis, but this was not statistically significant (OR: 0.581, p = 0.108, Table 3). The gene discussed is TNF; the disease is metastatic neoplasm.